-+ 0.00%
-+ 0.00%
-+ 0.00%

Immutep reports positive interim Phase I data for autoimmune drug candidate IMP761 at EULAR 2026

PUBT·06/04/2026 00:11:46
Listen to the news
Immutep reports positive interim Phase I data for autoimmune drug candidate IMP761 at EULAR 2026
  • Immutep flagged positive interim Phase I data for autoimmune candidate IMP761, with results set for presentation at EULAR 2026 on June 4.
  • The first-in-human trial in healthy volunteers met its primary goal, showing favorable safety and tolerability.
  • Early readouts showed pharmacodynamic activity consistent with immunosuppressive effects versus placebo, supporting further development in autoimmune disease.
  • The pharmacokinetic profile supports dosing about once every four weeks, shaping the program’s Phase II planning.
  • Additional trial updates are scheduled for H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.